Your browser doesn't support javascript.
loading
Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.
Naing, Aung; Wong, Deborah J; Infante, Jeffrey R; Korn, W Michael; Aljumaily, Raid; Papadopoulos, Kyriakos P; Autio, Karen A; Pant, Shubham; Bauer, Todd M; Drakaki, Alexandra; Daver, Naval G; Hung, Annie; Ratti, Navneet; McCauley, Scott; Van Vlasselaer, Peter; Verma, Rakesh; Ferry, David; Oft, Martin; Diab, Adi; Garon, Edward B; Tannir, Nizar M.
Afiliação
  • Naing A; MD Anderson Cancer Center, Houston, TX, USA. Electronic address: anaing@mdanderson.org.
  • Wong DJ; David Geffen School of Medicine, TRIO-US, University of California Los Angeles, Los Angeles, CA, USA.
  • Infante JR; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
  • Korn WM; University of California San Francisco, San Francisco, CA, USA.
  • Aljumaily R; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Papadopoulos KP; START Center for Cancer Care, San Antonio, TX, USA.
  • Autio KA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Pant S; MD Anderson Cancer Center, Houston, TX, USA; Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA.
  • Drakaki A; David Geffen School of Medicine, TRIO-US, University of California Los Angeles, Los Angeles, CA, USA.
  • Daver NG; MD Anderson Cancer Center, Houston, TX, USA.
  • Hung A; ARMO BioSciences, Redwood City, CA, USA.
  • Ratti N; ARMO BioSciences, Redwood City, CA, USA; Synthkine, Menlo Park, USA.
  • McCauley S; ARMO BioSciences, Redwood City, CA, USA; Synthkine, Menlo Park, USA.
  • Van Vlasselaer P; ARMO BioSciences, Redwood City, CA, USA.
  • Verma R; ARMO BioSciences, Redwood City, CA, USA.
  • Ferry D; Eli Lilly and Company, New York City, NY, USA.
  • Oft M; ARMO BioSciences, Redwood City, CA, USA; Synthkine, Menlo Park, USA.
  • Diab A; MD Anderson Cancer Center, Houston, TX, USA.
  • Garon EB; David Geffen School of Medicine, TRIO-US, University of California Los Angeles, Los Angeles, CA, USA.
  • Tannir NM; MD Anderson Cancer Center, Houston, TX, USA.
Lancet Oncol ; 20(11): 1544-1555, 2019 11.
Article em En | MEDLINE | ID: mdl-31563517
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polietilenoglicóis / Protocolos de Quimioterapia Combinada Antineoplásica / Interleucina-10 / Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos / Nivolumabe / Neoplasias Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polietilenoglicóis / Protocolos de Quimioterapia Combinada Antineoplásica / Interleucina-10 / Anticorpos Monoclonais Humanizados / Receptor de Morte Celular Programada 1 / Antineoplásicos Imunológicos / Nivolumabe / Neoplasias Tipo de estudo: Clinical_trials Limite: Aged / Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article